Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
| ▸ | GABRP | O00591 | 1/20 | 0.36 |
| ▸ | GABRD | O14764 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.36 |
| ▸ | GABRE | P78334 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.36 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30779755 | 0.89 | CYP2C19 (0.36) | CYP2C19POLBGAATSHRAPLNR | |
| SCHEMBL16632557 | 0.82 | HSD11B1 (0.34) | TSHRHSD11B1ALDH1A1HPGD | |
| SCHEMBL474269 | 0.81 | ATM (0.38) | CYP2C19POLBGAACYP1A2ALOX15 | |
| SCHEMBL474268 | 0.81 | ATM (0.38) | CYP2C19POLBGAACYP1A2ALOX15 | |
| SCHEMBL28795662 | 0.81 | ATM (0.38) | CYP2C19POLBGAACYP1A2ALOX15 | |
| SCHEMBL652433 | 0.79 | NOTUM (0.46) | POLBMAPTALDH1A1NOTUMLMNA | |
| SCHEMBL2875175 | 0.79 | NOTUM (0.46) | POLBMAPTALDH1A1NOTUMLMNA | |
| SCHEMBL2875954 | 0.79 | NOTUM (0.46) | POLBMAPTALDH1A1NOTUMLMNA | |
| SCHEMBL21178530 | 0.79 | GABRR1 (0.39) | CYP2C19POLBGAAALDH1A1KDM4E | |
| SCHEMBL2896263 | 0.79 | GABRR1 (0.39) | CYP2C19POLBGAAALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008778-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-12286437-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2025-04-29 | — | — | US | disclosed |
| US-20240398963-A1 | DRUG DELIVERY SYSTEM FOR LOCALLY DELIVERING THERAPEUTIC AGENTS AND USES THEREOF | COVAL BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2024-12-05 | — | — | US | disclosed |
| CN-118955409-A | Cardiac sarcomere inhibitors | 赛特凯恩蒂克公司 | 2024-11-15 | — | — | CN | disclosed |
| US-20240309011-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2024-09-19 | — | — | US | disclosed |
| CN-112867539-B | Cardiac sarcomere inhibitors | 赛特凯恩蒂克公司 | 2024-08-06 | — | — | CN | disclosed |
| CN-111094233-B | Compounds, compositions, and methods | 戴纳立制药公司 | 2024-03-15 | — | — | CN | disclosed |
| US-11919909-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| CN-117500802-A | LACTIVICIN compounds, their preparation and their use as antibacterial agents | 费多拉制药有限公司 | 2024-02-02 | — | — | CN | disclosed |
| EP-4301760-A1 | CARDIAC SARCOMERE INHIBITORS | Cytokinetics, Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| WO-2006071017-A1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM. CO., LTD. (KR) | 2006-07-06 | — | — | WO | disclosed |
| EP-1611127-A2 | 4-SUBSTITUED QUINOLEIN DERIVATIVES WITH ANTIMICROBIAL ACTIVITY | Aventis Pharma S.A. (FR) | 2006-01-04 | — | — | EP | disclosed |
| US-20050245563-A1 | Chk-1 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| WO-2005028474-A2 | PYRAZOLOQUINOLINE DERIVATIVES AS CHK-1 INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
| EP-1438046-A4 | THIAZOLE BENZAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING CELL PROLIFERATION, AND METHODS FOR THEIR USE | AGOURON PHARMA (US) | 2004-10-20 | — | — | EP | disclosed |
| WO-2004087647-A2 | 4-SUBSTITUTED QUINOLEIN DERIVATIVES WITH ANTIMICROBIAL ACTIVITY | AVENTIS PHARMA S.A. (FR) | 2004-10-14 | — | — | WO | disclosed |
| EP-1438046-A2 | THIAZOLE BENZAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING CELL PROLIFERATION, AND METHODS FOR THEIR USE | AGOURON PHARMACEUTICALS, INC. (US) | 2004-07-21 | — | — | EP | disclosed |
| US-6720346-B2 | (4-AMINOTHIAZOL-2-YLAMINO)-BENZAMIDE COMPOUNDS; PROTEIN KINASE INHIBITORS; CANCER; AUTOIMMUNE, VIRAL, FUNGAL, NEURODEGENERATIVE, AND CARDIOVASCULAR DISORDERS | AGOURON PHARMACEUTICALS, INC. | 2004-04-13 | — | — | US | disclosed |
| US-20030225147-A1 | Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use | AGOURON PHARMACEUTICALS INC. | 2003-12-04 | — | — | US | disclosed |
| WO-2003004467-A2 | THIAZOLE BENZAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING CELL PROLIFERATION, AND METHODS FOR THEIR USE | AGOURON PHARMACEUTICALS, INC. (US) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | CHKA, CHKB, CHEK1 | CYP2C19 4763/4885POLB 3257/4885GAA 2750/4885 |
| US-11919909-B2 | Cardiac sarcomere inhibitors | TNNI3, TNNT2, TNNC1 | CYP2C19 3726/4885POLB 3683/4885GAA 3290/4885 |
| US-20030225147-A1 | Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use | TK1, MKI67, CDKN1A | CYP2C19 193/4885POLB 3006/4885GAA 1088/4885 |
| US-12286437-B2 | Cardiac sarcomere inhibitors | TNNI3, TNNT2, TNNC1 | CYP2C19 3726/4885POLB 3683/4885GAA 3290/4885 |
| US-20240309011-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, TNNT2, TNNC1 | CYP2C19 3726/4885POLB 3683/4885GAA 3290/4885 |
| US-20260008778-A1 | COMPOUNDS AND USES THEREOF | BRD9, BCL9L, BCL9 | CYP2C19 1005/4885POLB 641/4885GAA 1384/4885 |
| US-20240398963-A1 | DRUG DELIVERY SYSTEM FOR LOCALLY DELIVERING THERAPEUTIC AGENTS AND USES THEREOF | TIE1, KDR, TEK | CYP2C19 4838/4885POLB 2296/4885GAA 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.